EVALUATION OF COMBINED ANTIDEPRESSANT AND TRANQUILIZING DRUG (AMITRIPTYLINE-PERPHENAZINE) IN THE TREATMENT OF HOSPITALIZED CHRONIC SCHIZOPHRENIC PATIENTS
Abstract
Nineteen hospitalized, chronic female schizophrenics were treated with combined amitriptyline-perphenezine for a period of 12 weeks.
Patients were evaluated initially and during the study in terms of standard rating scales, ward behavior, and global clinical judgment.
Observations and test data indicate that the patients as a group showed improvement, and the combination of amitriptyline- perphenezine seems compatible. However, since this pilot study did not include a placebo control, no definite conclusion can be drawn at this time. The results are sufficiently encouraging to warrant controlled clinical trial.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
